<qa>  To estimate progression free survival after treatment with venetoclax in combination with obinutuII. To estimate progression free survival PFS after treatment with venetoclax in combination with obinutuzumab and ibrutinib in patients with relapsedrefractory or previously untreated patients with CLL. 